FDAapproval95% confidence
FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable approval decision relevant to Barr; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Oncology · Chemotherapy
- Sub-indication
- General
Related signal: FDA Approval Update for TREXALL (Methotrexate Sodium) by Barr